Thu, Oct 30, 2014, 11:18 AM EDT - U.S. Markets close in 4 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

AstraZeneca PLC Message Board

  • bluecheese4u bluecheese4u Oct 25, 2012 2:12 AM Flag

    AstraZeneca PLC THIRD QUARTER AND NINE MONTHS RESULTS 2012

    AstraZeneca PLC THIRD QUARTER AND NINE MONTHS RESULTS 2012

    London, 25 October 2012

    As expected, the revenue decline in the third quarter reflected the ongoing effect from the loss
    of exclusivity on several brands. Continued disciplined management of operating expenses
    and proceeds from the sale of Nexium OTC rights mitigated the impact of the revenue decline
    on Core operating profit. Financial targets for full year unchanged.
    Revenue for the third quarter was $6,682 million, down 15 percent at constant exchange rates (CER).
    -Loss of exclusivity on several brands and the disposals of Astra Tech and Aptium were the key drivers of
    the revenue decline.
    -Strong growth for Symbicort, Faslodex, Iressa and ONGLYZATM.
    -Emerging Markets revenue increased by 6 percent at CER. There was 23 percent revenue growth in
    China and in Russia in the third quarter. Continued weak performance in Mexico negatively impacted
    Emerging Markets revenue growth by more than 2 percentage points.
    Core EPS was $1.51 in the third quarter, an 8 percent decline at CER.
    -Core EPS benefited from the lower number of shares outstanding resulting from net share repurchases.
    Reported EPS in the third quarter was $1.22, a 50 percent decline at CER.
    -Reported EPS in the third quarter last year included $1.08 per share from the sale of Astra Tech.
    Expansion of the diabetes alliance with Bristol-Myers Squibb was completed on 8 August. Alliance
    sales teams began promotion of the Amylin diabetes product portfolio in the US in October.
    Year to date net share repurchases totalled $2.3 billion. Suspension of share repurchase programme
    announced on 1 October.
    Core EPS target range for the full year maintained at $6.00 to $6.30.

    astrazeneca

 
AZN
72.06+0.53(+0.74%)11:17 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.